Literature DB >> 33586864

NK cells in antibody-mediated rejection - Key effector cells in microvascular graft damage.

Megan A O'Neill1, Luis G Hidalgo1.   

Abstract

Antibody-mediated rejection (ABMR) stands as the major limitation to long-term transplant outcome. The immunologic understanding of ABMR continues to progress and has identified natural killer (NK) cells as key effector cells promoting and coordinating the immune attack on the graft microvascular endothelium. This review discusses the current concepts outlining the different ways that allow for NK cell recognition of graft endothelial cells which includes antibody-dependent as well as independent processes.
© 2021 John Wiley & Sons Ltd.

Year:  2021        PMID: 33586864     DOI: 10.1111/iji.12532

Source DB:  PubMed          Journal:  Int J Immunogenet        ISSN: 1744-3121            Impact factor:   1.466


  4 in total

Review 1.  Small Extracellular Vesicles in Transplant Rejection.

Authors:  Justyna E Gołębiewska; Anna Wardowska; Monika Pietrowska; Anna Wojakowska; Alicja Dębska-Ślizień
Journal:  Cells       Date:  2021-11-03       Impact factor: 6.600

Review 2.  Microvascular Inflammation of the Renal Allograft: A Reappraisal of the Underlying Mechanisms.

Authors:  Emilie Lebraud; Maëva Eloudzeri; Marion Rabant; Baptiste Lamarthée; Dany Anglicheau
Journal:  Front Immunol       Date:  2022-03-22       Impact factor: 7.561

3.  Imagining a Better Outcome for Chronic Antibody-Mediated Rejection-Will Blocking Interleukin-6 Signaling Help?

Authors:  Thangamani Muthukumar; R John Crew
Journal:  Kidney Int Rep       Date:  2022-03-03

4.  Weak Expression of Terminal Complement in Active Antibody-Mediated Rejection of the Kidney.

Authors:  Gesa Tiller; Rosa G M Lammerts; Jessy J Karijosemito; Firas F Alkaff; Arjan Diepstra; Robert A Pol; Anita H Meter-Arkema; Marc A Seelen; Marius C van den Heuvel; Bouke G Hepkema; Mohamed R Daha; Jacob van den Born; Stefan P Berger
Journal:  Front Immunol       Date:  2022-04-13       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.